Compass Pathways: Built The FDA's Way, Valued At 0.57x Spravato's SalesSeeking Alpha · 3 days ago
Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness DayBusiness Wire · Oct 14, 2026
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire · Oct 2, 2026
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stock Has Consensus Target Price of $23.36 According to BrokeragesDefense World · Oct 1, 2026
Compass Pathways Appoints Kelley Boucher as Chief People OfficerBusiness Wire · Sep 30, 2026
Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 LaunchMarketBeat · Sep 24, 2026COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.46 | -$0.36 | Beat |
| May 13, 2026 | -$0.45 | -$0.30 | Beat |
| Mar 24, 2026 | -$0.41 | -$1.00 | Miss |
| Nov 4, 2025 | -$0.40 | -$1.44 | Miss |
| Jul 31, 2025 | -$0.37 | -$0.38 | Miss |
| May 8, 2025 | -$0.47 | -$0.24 | Beat |